Respiratorius AB (publ)
Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company's products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was inc… Read more
Respiratorius AB (publ) (HF00) - Total Assets
Latest total assets as of September 2025: €33.20 Million EUR
Based on the latest financial reports, Respiratorius AB (publ) (HF00) holds total assets worth €33.20 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Respiratorius AB (publ) - Total Assets Trend (2021–2024)
This chart illustrates how Respiratorius AB (publ)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Respiratorius AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
Respiratorius AB (publ)'s total assets of €33.20 Million consist of 25.7% current assets and 74.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 24.7% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €23.04 Million | 74.3% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Respiratorius AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Respiratorius AB (publ)'s current assets represent 25.7% of total assets in 2024, a decrease from 46.1% in 2021.
- Cash Position: Cash and equivalents constituted 24.7% of total assets in 2024, down from 44.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 74.0% of total assets, an increase from 53.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 74.3% of total assets.
Respiratorius AB (publ) Competitors by Total Assets
Key competitors of Respiratorius AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Respiratorius AB (publ) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Respiratorius AB (publ) generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Respiratorius AB (publ) is currently not profitable relative to its asset base.
Respiratorius AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.87 | 13.60 | 13.60 |
| Quick Ratio | 9.87 | 13.60 | 13.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €8.10 Million | € 8.73 Million | € 8.73 Million |
Respiratorius AB (publ) - Advanced Valuation Insights
This section examines the relationship between Respiratorius AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 11.7% |
| Total Assets | €31.02 Million |
| Market Capitalization | $752.26K USD |
Valuation Analysis
Below Book Valuation: The market values Respiratorius AB (publ)'s assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Respiratorius AB (publ)'s assets grew by 11.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Respiratorius AB (publ) (2021–2024)
The table below shows the annual total assets of Respiratorius AB (publ) from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €31.02 Million | +11.69% |
| 2023-12-31 | €27.77 Million | -22.33% |
| 2022-12-31 | €35.75 Million | -42.34% |
| 2021-12-31 | €62.01 Million | -- |